Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Posted
Benzinga Neuro (via Benzinga)
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment.
read more
Equities,
FDA,
Food and Drug Administration,
Kaustubh Bagalkote,
News,
REGN,
Health Care,
Markets,
REGN,
US75886F1075,
News,
Equities,
Health Care,
Markets,
Benzinga
